Advertisement

Picture Berlin Partner BIO 2024 International Convention San Diego 650x100px
Document › Details

Tubulis GmbH. (4/20/23). "Press Release: Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients". Munich.

Organisations Organisation Tubulis GmbH
  Group Tubulis (Group)
  Organisation 2 Bristol Myers Squibb Co. (BMS) (NYSE: BMY)
  Group Bristol Myers Squibb (BMS) (Group)
Products Product antibody-drug conjugate (ADC)
  Product 2 antibody-drug conjugates (ADC) technology
Persons Person Schumacher, Dominik (Tubulis 201907– Managing Director (CEO) + Co-Founder)
  Person 2 May, Stephanie (Trophic Communications 201801 before MacDougall European Office)
     


> Companies join forces bringing together Bristol Myers Squibb’s (BMS) deep oncology and clinical development expertise and Tubulis’ differentiated and unique approach to Antibody-Drug-Conjugate (ADC) design with the goal of delivering the true therapeutic potential of ADCs.

> Tubulis to receive upfront payment of $22.75 million and milestone payments potentially totaling over $1 billion plus tiered royalties on net product sales.

> BMS to obtain access to Tubulis’ proprietary P5 conjugation and Tubutecan platforms to develop versatile and customizable antibody-drug conjugates for cancer treatment.


Tubulis and Bristol Myers Squibb (NYSE: BMY) today announced that they have entered into a strategic license agreement to develop differentiated antibody-drug conjugates (ADCs).

Through the license agreement, Bristol Myers Squibb will gain exclusive rights to access Tubulis’ Tubutecan payloads in combination with Tubulis’ proprietary P5 conjugation platform for the development of a selected number of highly differentiated ADCs to treat solid tumors. P5 and Tubutecans facilitate the generation of ultra-stable ADCs that have the potential to actively reduce unwanted target-independent toxicities and are optimized for on-target delivery of potent topoisomerase-1 inhibitors.

The terms of the agreement include an upfront payment of $22.75 million to Tubulis in addition to the potential for over $1 billion in development, regulatory, and commercial milestone payments plus royalty payments on resulting marketed products. Following antibody target selection by Bristol Myers Squibb, Tubulis will provide the company with its linker-payload to generate a uniquely matched ADC for each antibody. Bristol Myers Squibb will assume sole responsibility for development, manufacturing, and commercialization of the resulting ADC candidates.

“This strategic agreement with Bristol Myers Squibb is an important validation of the potential of our approach in developing next-generation ADC-based therapeutics and our cutting-edge ADC conjugation technologies that accommodate advanced ADC design to tackle tumors with high-unmet medical need,” said Dominik Schumacher, PhD, CEO and co-founder of Tubulis. “We are committed to transforming oncology treatment paradigms and to deliver better outcomes for cancer patients. Joining forces with BMS, a leading global oncology company, is a significant step toward achieving that goal.”

“ADCs play a promising role in cancer therapy, and Tubulis’ differentiated technologies offer opportunities toovercome current challenges in the development of safe and effective ADC therapeutics,” said Emma Lees, PhD, Senior Vice President, Research and Early Development and Head, Mechanisms of Cancer Resistance Thematic Research Center at Bristol Myers Squibb. “With the P5 platform, we will be able to pair the right antibody with the right payload and thus provide potential for meaningful therapeutic benefits for patients with solid tumors. We are looking forward to a fruitful partnership with the Tubulis team.”


About Tubulis

Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its growing pipeline and will continue to collaborate with industry partners to usher in a new ADC era and deliver better outcomes for patients. Visit www.tubulis.com or follow us on LinkedIn and Twitter.


Contacts

For Tubulis:
Dominik Schumacher, CEO & Co-Founder
Phone: +49 175 800 5594
Email: contact@tubulis.com

Media Requests for Tubulis:
Trophic Communications
Stephanie May or Marie Weickert
Phone: + 49 (0) 171 185 5682
Email: tubulis@trophic.eu

   
Record changed: 2024-01-20

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Tubulis (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Top News Healthtech Company Mika 650x300px




» top